Top 10 Pharma Corporate Venture Capital

Transaction Overview

Rosetta Capital completed a secondary transaction to acquire a portfolio of over 10 life sciences assets from a Corporate Venture Capital arm of a Top 10 Pharma company. This enabled the Corporate Venture Capital arm to redeploy capital into assets that aligned strategically with the parent company.

Selected exits from the portfolio include the sale of Novimmune to Sobi and the GlycoMimetics and Paratek IPOs on NASDAQ.

Supporting portfolio companies for the next growth phase

Rosetta Capital supported the portfolio companies acquired in the transaction through the growth phase and made several follow-on investments